@UngeimpfterArzt @anton_pavelich @wodarg Übrigens: die Kinetik des Ak Titers (Schutzkorrelat) nach CoV2 Infektion kennt man schon seit über 2 Jahren… https://t.co/M8kJ0L7Qwp https://t.co/FVrfOELBj8 https://t.co/FK80Uoe9Pj
@margal @BigMarky9 @PaganLady3 @RosalynEves @elforesto Can you provide the studies you were reviewing to get the "inverse relationship" you discuss on viral load? According to the studies I've read viral load that invades full body seems to be the desi…
RT @konishi_apu_slb: #長期微熱組や長期不調組を救ってください https://t.co/xr7XuiaV9Q もしかしてウイルスが消えるまでの期間って思ってたよりもずっとずうううっと長いんじゃないかって
@BartosVl https://t.co/4HxT3AsXxf studie o virové náloži.
#長期微熱組や長期不調組を救ってください https://t.co/xr7XuiaV9Q もしかしてウイルスが消えるまでの期間って思ってたよりもずっとずうううっと長いんじゃないかって
@GamerGirl_Hope @RpsAgainstTrump It simply makes sense, but since you asked, I found you an article. I'd find more, but I think you should do the work. "Severely ill patients had more prolonged viral shedding in a variety of tissues than mildly ill pat…
COVID-19 Logic: severely ill patients have viral shedding for 20-40 days after onset of disease, while the mildly ill have no detectable virus RNA 10 days after onset. Mildly ill patients also had lower IgM response compared to the severe group. https:…
RT @jclinicalinvest: Just published: Kinetics of viral load and antibody response in relation to #COVID_19 severity: https://t.co/KYqZpTZFJ…
RT @jclinicalinvest: Serological responses and viral shedding vary with #COVID_19 severity: https://t.co/lxbw8y1RON Accompanying commentary by @ACasadevall1, @DrMJoyner and Liise-anne Pirofski: https://t.co/Y9SoZWpYKf https://t.co/GKl4OFkKFx
Tak tohle je OPRAVDU zajímavé.
RT @jclinicalinvest: Serological responses and viral shedding vary with #COVID_19 severity: https://t.co/lxbw8y1RON Accompanying commentary by @ACasadevall1, @DrMJoyner and Liise-anne Pirofski: https://t.co/Y9SoZWpYKf https://t.co/GKl4OFkKFx
Tak tohle je OPRAVDU zajímavé.
RT @SArgenteus: Tak tohle je OPRAVDU zajímavé. https://t.co/OQzOuoVYWR
RT @jclinicalinvest: Serological responses and viral shedding vary with #COVID_19 severity: https://t.co/KYqZpTZFJ2 Accompanying commentary…
Tak tohle je OPRAVDU zajímavé.
RT @jclinicalinvest: Serological responses and viral shedding vary with #COVID_19 severity: https://t.co/KYqZpTZFJ2 Accompanying commentary…
Serological responses and viral shedding vary with #COVID_19 severity: https://t.co/KYqZpTZFJ2 Accompanying commentary by @ACasadevall1, @DrMJoyner and Liise-anne Pirofski: https://t.co/gSRfAO6fqb https://t.co/N6nzuWVeDT
@PetriTommila @senjalarsen Toinen Kiinasta missä sama tulos https://t.co/NV9nz4BidV vasta-aineita enemmän vakavassa tautimuodossa. Myös tiedetään että muilla koronaviruksilla immuniteetti hiipuu nopeasti. Eikö se ole aika ilmeistä että paha tauti antaa ke…
RT @hichachu: RT-PCR で COVID-19 が確認された 2 群の COVID-19 患者を登録した。機械換気を必要とする ICU の重症患者 12 例と隔離病棟の軽症患者 11 例を含む。臨床検体を連続的に採取した。 重症患者の多くは発症後20~40日の間…
RT @hichachu: RT-PCR で COVID-19 が確認された 2 群の COVID-19 患者を登録した。機械換気を必要とする ICU の重症患者 12 例と隔離病棟の軽症患者 11 例を含む。臨床検体を連続的に採取した。 重症患者の多くは発症後20~40日の間…
RT @hichachu: RT-PCR で COVID-19 が確認された 2 群の COVID-19 患者を登録した。機械換気を必要とする ICU の重症患者 12 例と隔離病棟の軽症患者 11 例を含む。臨床検体を連続的に採取した。 重症患者の多くは発症後20~40日の間…
RT @hichachu: RT-PCR で COVID-19 が確認された 2 群の COVID-19 患者を登録した。機械換気を必要とする ICU の重症患者 12 例と隔離病棟の軽症患者 11 例を含む。臨床検体を連続的に採取した。 重症患者の多くは発症後20~40日の間…
RT @hichachu: RT-PCR で COVID-19 が確認された 2 群の COVID-19 患者を登録した。機械換気を必要とする ICU の重症患者 12 例と隔離病棟の軽症患者 11 例を含む。臨床検体を連続的に採取した。 重症患者の多くは発症後20~40日の間…
RT-PCR で COVID-19 が確認された 2 群の COVID-19 患者を登録した。機械換気を必要とする ICU の重症患者 12 例と隔離病棟の軽症患者 11 例を含む。臨床検体を連続的に採取した。 重症患者の多くは発症後20~40日の間、様々な組織にウイルスが拡散していた(8/12、66.7%)…
RT @jclinicalinvest: Just published: Kinetics of viral load and antibody response in relation to #COVID_19 severity: https://t.co/KYqZpTZFJ…
RT @meed_ref: Kinetics of viral load and antibody response in relation to COVID-19 severity https://t.co/jl07UnnmhW Included at COVID-19…
RT @jclinicalinvest: Just published: Kinetics of viral load and antibody response in relation to #COVID_19 severity: https://t.co/KYqZpTZFJ…
RT @meed_ref: Kinetics of viral load and antibody response in relation to COVID-19 severity https://t.co/jl07UnnmhW Included at COVID-19…
Kinetics of viral load and antibody response in relation to COVID-19 severity https://t.co/jl07UnnmhW Included at COVID-19 & ANTIVIRALS https://t.co/HJyKalLaLq #MeedCOVID19 @Sociedad_SEMI @sev_virologia @ResidentesSEMI @SEMicrobiologia @SEIMC_ …
RT @jclinicalinvest: ICYMI: Commentary by @ACasadevall1, @DrMJoyner, & Liise-Anne Pirofski: SARS-CoV-2 viral load and antibody responses: t…
RT @jclinicalinvest: ICYMI: Commentary by @ACasadevall1, @DrMJoyner, & Liise-Anne Pirofski: SARS-CoV-2 viral load and antibody responses: t…
New paper on kinetics of viral load/ab response in relation to #COVID19 severity. Highlights: Mild & severe disease patients had neutralizing IgG 10days post-symptom onset. Virus persisted longer in severe disease patients. Only abs from COVID-19 pa…
RT @jclinicalinvest: ICYMI: Commentary by @ACasadevall1, @DrMJoyner, & Liise-Anne Pirofski: SARS-CoV-2 viral load and antibody responses: t…
ICYMI: Commentary by @ACasadevall1, @DrMJoyner, & Liise-Anne Pirofski: SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy: https://t.co/gSRfAO6fqb Related article: https://t.co/KYqZpTZFJ2 #Covid_19 #InfectiousDis…
RT @jclinicalinvest: Just published: Kinetics of viral load and antibody response in relation to #COVID_19 severity: https://t.co/KYqZpTZFJ…
RT @DanielJDrucker: Additional characterization of viral load and antibody immune responses against SARS-CoV-2 in relation to #COVID19 seve…
RT @jclinicalinvest: Just published: Kinetics of viral load and antibody response in relation to #COVID_19 severity: https://t.co/KYqZpTZFJ…
RT @DanielJDrucker: Additional characterization of viral load and antibody immune responses against SARS-CoV-2 in relation to #COVID19 seve…
RT @DanielJDrucker: Additional characterization of viral load and antibody immune responses against SARS-CoV-2 in relation to #COVID19 seve…
Additional characterization of viral load and antibody immune responses against SARS-CoV-2 in relation to #COVID19 severity @jclinicalinvest https://t.co/XXp2orjs2M https://t.co/qqaIkCRoVH
RT @jclinicalinvest: Just published: Kinetics of viral load and antibody response in relation to #COVID_19 severity: https://t.co/KYqZpTZFJ…
RT @jclinicalinvest: Just published: Kinetics of viral load and antibody response in relation to #COVID_19 severity: https://t.co/KYqZpTZFJ…
RT @jclinicalinvest: Just published: Kinetics of viral load and antibody response in relation to #COVID_19 severity: https://t.co/KYqZpTZFJ…
Diferencias de diseminación viral entre casos graves y leves. | #COVID19SV Los resultados mostraron que la mayoría de los pacientes severos tuvieron desprendimiento viral durante 20 ~ 40 días después del inicio de la enfermedad. https://t.co/1zNXQDWSIj
Just published: Kinetics of viral load and antibody response in relation to #COVID_19 severity: https://t.co/KYqZpTZFJ2 https://t.co/xisbq5um56